CAP 1002

Drug Profile

CAP 1002

Alternative Names: Allogeneic adult stem cell therapy for myocardial infarction - Capricor; Allogeneic cardiosphere-derived cells - Capricor; Allogeneic CDCs - Capricor; Allogenic derived cells - Capricor; CAP-1002

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator Capricor
  • Developer Capricor; Capricor Therapeutics; Medical University of South Carolina
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Phase II Heart failure; Myocardial infarction
  • Phase I/II Cardiomyopathies; Duchenne muscular dystrophy

Most Recent Events

  • 18 Jul 2017 CAP 1002 receives Rare Pediatric Disease Designation from the US FDA for Duchenne muscular dystrophy
  • 06 Jul 2017 Janssen Biotech terminates its options agreement for CAP 1002
  • 12 May 2017 Capricor Therapeutics plans a repeat-dose clinical trial for Duchenne muscular dystrophy in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top